John Davis, PhD

Vice President, Head of Preclinical Development,
Dyne Therapeutics, Waltham, MA

John Davis is responsible for developing preclinical strategies necessary for underwriting clinical trials from First In Human through Phase III at Dyne Therapeutics, a genetic medicine company. John has over 20 years of experience in a global biopharmaceutical setting with a breadth of portfolio support that includes antisense oligonucleotide, small molecule and biologic programs. John received a PhD in Molecular Toxicology at Purdue University and completed a postdoctoral fellowship at the University of New Mexico.

See also: https://www.dyne-tx.com